BioCentury | May 15, 2018
Distillery Therapeutics

Neurology

INDICATION: Spinal cord injury (SCI) Cell culture and mouse studies suggest antagonizing OPRL1 alone or in combination with inhibiting its downstream effector RTN4R could help treat SCI. In primary mouse cortical neurons subjected to scrape...
BioCentury | Jan 11, 2017
Distillery Therapeutics

Neurology

...INDICATION: Stroke Mouse studies suggest inhibiting signaling between RTN4R , RTN4RL2 and their ligands could help...
...I testing for spinal cord injury (SCI). TARGET/MARKER/PATHWAY: Reticulon 4 receptor (RTN4R; NGR); reticulon 4 receptor-like 2 (RTN4RL2; NgR2...
...MAG) Oligodendrocyte myelin glycoprotein (OMG) (OMGP) Reticulon 4 (RTN4) (NOGO-A) (NOGO) (NOGO-B) Reticulon 4 receptor (RTN4R) (NGR) Reticulon 4 receptor-like 2 (RTN4RL2) (NgR2...
BioCentury | Jan 7, 2016
Strategy

Imaging

TECHNOLOGY: Fluorescence labeling of corticospinal tract axons to monitor axon regeneration following spinal cord injury (SCI) Fluorescence labeling of corticospinal tract axons could help screen for molecular targets involved in promoting axon regeneration after SCI....
BioCentury | Jul 14, 2014
Finance

2Q Stock Wrap-Up: Large and in charge

In contrast to the first quarter in which all market cap segments gained ground, only the large caps finished 2Q14 in the black. Gainers outnumbered decliners 20-12 in the over $5 billion segment, which was...
BioCentury | May 12, 2014
Clinical News

NGR-hTNF: Phase III data

Top-line data from the double-blind, international Phase III NGR015 trial in 400 patients with MPM whose disease progressed after a pemetrexed-based chemotherapy showed that second-line treatment with once-weekly 0.8 µg/m 2 NGR-hTNF plus best investigator's...
BioCentury | May 12, 2014
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) slipped $2.25 to $152.87 last week after FDA granted full approval to Soliris eculizumab to treat atypical hemolytic uremic syndrome (aHUS). The agency granted accelerated approval for Soliris for...
BioCentury | May 6, 2014
Clinical News

MolMed's NGR-hTNF misses in malignant pleural mesothelioma

MolMed S.p.A. (Milan:MLM) said second-line treatment with once-weekly NGR-hTNF plus best investigator's choice (BIC) missed the primary endpoint of improving overall survival (OS) vs. placebo plus BIC in the Phase III NGR015 trial to treat...
BioCentury | Jul 1, 2013
Finance

3Q Financial Markets Preview: Punctuated equilibrium

Buysiders are viewing 3Q13 as a relatively quiet quarter punctuated by some important clinical and commercial milestones for a few of biotech's bigger names, notably Celgene Corp. and Biogen Idec Inc. The under $200 million...
BioCentury | Jun 3, 2013
Clinical News

NGR-hTNF: Additional Phase II data

Additional data from the open-label, Italian Phase II NGR014 trial in 121 chemotherapy-naïve patients with stage IIIb/IV NSCLC showed that 0.8 µg/m 2 NGR-hTNF every 3 weeks plus cisplatin and pemetrexed or gemcitabine led to...
BioCentury | Jun 3, 2013
Clinical News

NGR-hTNF: Interim Phase II data

Interim data from 55 evaluable patients in the open-label, European Phase II Study NGR016 trial showed that weekly IV infusions of 0.8 µg/m 2 NGR-hTNF in combination with doxorubicin (Arm C) met the primary endpoint...
Items per page:
1 - 10 of 58